Benralizumab

本瑞利珠单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameBenralizumab
Drug Alias NameBenralizumabum本雷利珠单抗贝那利珠单抗Anti-interleukin-5 receptor alpha monoclonal antibodyAnti-IL5Ra monoclonal antibody +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-5 receptor subunit alpha inhibitors
TargetsInterleukin-5 receptor subunit alpha
Therapy Area/IndicationsEosinophilic AsthmaEosinophilic gastroenteritis (EG)Hypersensitivity, Immediate +[30] 
Global Approved IndicationsAsthma
Approved Indications in ChinaAsthma
Original Approved Country/TerritoryUnited States
Original Approved Date2017/11/14
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBiowa IncMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdKyowa Hakko Kirin Co LtdAstrazeneca Plc +[7] 
Inactive CompaniesKyowa Kirin Co LtdMedimmune LtdJohns Hopkins University +[5] 
Active IndicationsEosinophilic AsthmaHypersensitivity, ImmediateHypersensitivity +[18] 
Inactive IndicationsEosinophilic gastroenteritis (EG)Immune System DiseasesPemphigoid, Bullous +[12] 

Other Information

ATC CodeR03DX10
Related LinksWikipediaDrugBankKEGG